Volume 2 Supplement 3
CD4 T cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T cell responses resulting in potent antitumor effects
© Cho et al.; licensee BioMed Central Ltd. 2014
Published: 6 November 2014
Therapeutic cancer vaccines are an attractive alternative to conventional therapies to treat malignant tumors, and more importantly, to prevent recurrence after primary therapy. However, the availability of professional antigen-presenting cells (APCs) has been restricted by difficulties encountered in obtaining sufficient professional APCs for clinical use. We have prepared an alternative cellular vaccine with CD4 T cells that can be expanded easily to yield a pure and homogeneous population in vitro. To enhance their potency as a therapeutic vaccine, in vitro expanded CD4 T cells were transfected with RNAs encoding the costimulatory ligands CD80, 4-1BBL, or both (CD80-T, 4-1BBL-T, and CD80/4-1BBL-T cells, respectively). We observed augmented cell vitality in CD80/4-1BBL-T cells in vitro and in vivo. Significant CD8 T cell responses eliciting in vivo proliferation and cytotoxicity were obtained with CD80/4-1BBL-T cell vaccination compared to CD80-T and 4-1BBL-T cell vaccinations. Furthermore, CD80/4-1BBL-T cell immunization resulted in curing established EG7 tumors, resulting in the generation of memory CD8 T cell responses, and elicited therapeutic antitumor responses against B16 melanoma. These results suggest that CD4 T cells endowed with costimulatory ligands allow the design of effective vaccination strategies against cancer.
This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C0759).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.